A detailed history of Mackenzie Financial Corp transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Mackenzie Financial Corp holds 10,007 shares of DVAX stock, worth $126,388. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,007
Holding current value
$126,388
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.05 - $11.61 $100,570 - $116,181
10,007 New
10,007 $111,000
Q2 2022

Aug 10, 2022

SELL
$7.45 - $12.83 $120,615 - $207,717
-16,190 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$9.75 - $14.44 $32,175 - $47,652
3,300 Added 25.6%
16,190 $175,000
Q4 2021

Feb 14, 2022

BUY
$13.17 - $20.94 $25,641 - $40,770
1,947 Added 17.79%
12,890 $181,000
Q3 2021

Nov 08, 2021

BUY
$9.16 - $19.83 $100,237 - $216,999
10,943 New
10,943 $210,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.6B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.